Skip to content
10-Q

Quarterly Report

DAY ONE BIOPHARMACEUTICALS, INC.

0000950170-25-064436

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 101.36M sh
Shares Diluted Q1 2025 · Mar 31, 2025 102.71M sh
Shares Diluted Q1 2025 · Mar 31, 2024 86.68M sh
Capex Q1 2025 · Mar 31, 2025 $317K
Capex Q1 2025 · Mar 31, 2024 $0
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$59M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$49.73M
Short Term Investments Q1 2025 · Mar 31, 2025 $439.66M
Short Term Investments Q1 2025 · Dec 31, 2024 $406.75M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $33.36M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $124.97M
Stockholders Equity Q1 2025 · Mar 31, 2025 $479.51M
Stockholders Equity Q1 2025 · Dec 31, 2024 $502.75M
Stockholders Equity Q1 2025 · Mar 31, 2024 $296.81M
Stockholders Equity Q1 2025 · Dec 31, 2023 $346.54M
Current Liabilities Q1 2025 · Mar 31, 2025 $47.88M
Current Liabilities Q1 2025 · Dec 31, 2024 $73.45M
Total Liabilities Q1 2025 · Mar 31, 2025 $54.84M
Total Liabilities Q1 2025 · Dec 31, 2024 $80.04M
Current Assets Q1 2025 · Mar 31, 2025 $508.65M
Current Assets Q1 2025 · Dec 31, 2024 $562.33M
Total Assets Q1 2025 · Mar 31, 2025 $534.36M
Total Assets Q1 2025 · Dec 31, 2024 $582.79M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.35
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.72
Eps Basic Q1 2025 · Mar 31, 2025 −$0.35
Eps Basic Q1 2025 · Mar 31, 2024 −$0.72
Sga Expense Q1 2025 · Mar 31, 2025 $29.33M
Sga Expense Q1 2025 · Mar 31, 2024 $26.56M
Rd Expense Q1 2025 · Mar 31, 2025 $39.62M
Rd Expense Q1 2025 · Mar 31, 2024 $40.21M
Net Income Q1 2025 · Mar 31, 2025 −$36M
Net Income Q1 2025 · Mar 31, 2024 −$62.41M
Operating Income Q1 2025 · Mar 31, 2025 −$41.07M
Operating Income Q1 2025 · Mar 31, 2024 −$66.77M
Revenue Q1 2025 · Mar 31, 2025 $30.76M
Revenue Q1 2025 · Mar 31, 2024 $0